ImportantUpdates
Company's Board approved solid Q4/FY financial results: ₹107.66 Cr revenue & ₹13.11 Cr profit.
Par Drugs and Chemicals LimitedPAR · Filed with the exchange
Strong operating cash flow at ₹16.43 Cr.
Greenlit ₹90 Cr for liquid fund investments and renewed a ₹1.61 Cr banking facility.
Strategic restructuring faces regulatory delays, yet auditors affirm going concern.
No comments yet. Be the first.